Virtus LifeSci Biotech Products ETF (BBP)
| Assets | $20.99M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 350,004 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +4.33% |
| Volume | 576 |
| Open | 60.06 |
| Previous Close | 60.00 |
| Day's Range | 60.06 - 60.18 |
| 52-Week Low | 50.43 |
| 52-Week High | 69.12 |
| Beta | 0.62 |
| Holdings | 66 |
| Inception Date | Dec 17, 2014 |
About BBP
Fund Home PageThe Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is issued by Virtus Investment Partners.
Top 10 Holdings
19.75% of assets| Name | Symbol | Weight |
|---|---|---|
| Intra-Cellular Therapies, Inc. | ITCI | 2.52% |
| BridgeBio Pharma, Inc. | BBIO | 2.05% |
| Sage Therapeutics, Inc. | SAGE | 2.05% |
| Harmony Biosciences Holdings, Inc. | HRMY | 2.01% |
| Halozyme Therapeutics, Inc. | HALO | 1.93% |
| BeiGene, Ltd. | ONC | 1.90% |
| Blueprint Medicines Corporation | BPMC | 1.87% |
| Neurocrine Biosciences, Inc. | NBIX | 1.86% |
| Mirum Pharmaceuticals, Inc. | MIRM | 1.80% |
| Ironwood Pharmaceuticals, Inc. | IRWD | 1.77% |
News
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Late-stage biotech ETFs rally Monday on virus treatment hopes
Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel coronavirus. The ALPS Medical Breakthroughs ETF ...